The ₹1,823-crore market capitalisation company, which specialises in providing diagnostic services primarily through public-private partnerships, witnessed a dramatic improvement in profitability during the March quarter. The PAT margin expanded significantly to 21.66% from 8.42% in the preceding quarter, driven substantially by exceptional other income of ₹31.50 crores—a seven-fold increase from the typical quarterly run rate of ₹3-4 crores. This one-time windfall accounts for nearly the entire sequential profit surge, raising questions about the underlying operational performance.
The company's full-year FY26 performance tells a more measured story. For FY26, Krsnaa Diagnostics reported net sales of ₹772.77 crores and consolidated net profit of ₹101.44 crores, translating to healthy year-on-year growth of 7.78% and 31.75% respectively. The operating margin (excluding other income) improved modestly to 27.37% from 26.50% in FY25, indicating gradual operational efficiency gains rather than transformational change.
Financial Performance: Exceptional Gains Drive Q4 Surge
Krsnaa Diagnostics' Q4 FY26 revenue stood at ₹192.60 crores, registering modest sequential growth of 6.29% from ₹181.20 crores in Q3 FY26 and 3.50% year-on-year growth from ₹186.08 crores in Q4 FY25. The tepid top-line expansion contrasts sharply with the bottom-line surge, highlighting the disproportionate impact of non-operating income on quarterly profitability.
| Quarter | Revenue (₹ Cr) | QoQ Growth | Net Profit (₹ Cr) | QoQ Growth | PAT Margin |
|---|---|---|---|---|---|
| Mar'26 | 192.60 | +6.29% | 41.72 | +173.57% | 21.66% |
| Dec'25 | 181.20 | -12.03% | 15.25 | -36.33% | 8.42% |
| Sep'25 | 205.99 | +6.74% | 23.95 | +16.72% | 11.63% |
| Jun'25 | 192.98 | +3.71% | 20.52 | -0.77% | 10.63% |
| Mar'25 | 186.08 | +6.63% | 20.68 | +6.49% | 11.11% |
| Dec'24 | 174.51 | -6.35% | 19.42 | -0.92% | 11.13% |
| Sep'24 | 186.34 | — | 19.60 | — | 10.52% |
The operating profit (PBDIT) excluding other income stood at ₹54.88 crores in Q4 FY26, up 18.18% quarter-on-quarter but only 3.57% year-on-year. The operating margin (excluding other income) improved to 28.49% from 25.63% in the previous quarter, driven by better cost management as employee costs declined to ₹33.35 crores from ₹36.17 crores sequentially. However, the inclusion of exceptional other income of ₹31.50 crores inflated total PBDIT to ₹86.38 crores, creating an unsustainable gross margin of 38.58%.
Interest expenses rose to ₹12.08 crores in Q4 FY26 from ₹7.79 crores in Q3 FY26, reflecting higher borrowing costs as the company increased long-term debt to ₹18.50 crores from ₹5.50 crores in the previous fiscal year. Depreciation remained stable at ₹22.59 crores. The tax rate declined to 19.30% from 22.56% in the previous quarter, providing additional tailwinds to net profit growth. The effective tax rate of 19.30% in Q4 FY26 appears favourable compared to the full-year FY25 rate of 24.50%, warranting scrutiny regarding sustainability.
Operational Excellence: Modest Gains Overshadowed by One-Time Windfall
Stripping away the exceptional other income, Krsnaa Diagnostics' underlying operational performance in Q4 FY26 appears far less impressive. The company's core diagnostic services business generated operating profit (excluding other income) of ₹54.88 crores, translating to a margin of 28.49%—an improvement from 25.63% in Q3 FY26 but only marginally better than the 28.48% achieved in Q4 FY25. This suggests operational efficiency gains remain incremental rather than transformational.
⚠ The Other Income Anomaly
Q4 FY26 other income of ₹31.50 crores represents a staggering 727% increase from the ₹3.77 crores reported in Q3 FY26 and 617% higher than Q4 FY25's ₹4.39 crores. This exceptional item contributed nearly 61% of the quarter's operating profit (PBDIT) of ₹86.38 crores. Without this windfall, Q4 FY26 net profit would have been approximately ₹18-20 crores—broadly in line with the previous quarters—rather than the reported ₹41.72 crores. Investors should exercise caution in extrapolating Q4 profitability to future quarters.
The company's return on equity (ROE) improved to 9.16% in the latest period from an average of 8.50%, but remains weak by industry standards. Higher ROE indicates better capital efficiency and profitability—a metric where Krsnaa Diagnostics lags significantly behind peers such as Thyrocare Technologies (20.88% ROE) and Metropolis Healthcare (14.57% ROE). The company's return on capital employed (ROCE) stood at 11.01%, up from an average of 11.77%, but still reflects suboptimal deployment of capital.
Balance sheet quality presents a mixed picture. Shareholder funds increased to ₹882.77 crores in FY26 from ₹809.80 crores in FY25, supported by retained earnings. However, long-term debt tripled to ₹18.50 crores from ₹5.50 crores, and total current liabilities rose to ₹305.39 crores from ₹281.47 crores. The debt-to-EBITDA ratio of 0.83 remains manageable, and net debt-to-equity of 0.17 indicates low leverage. Fixed assets expanded to ₹670.38 crores from ₹647.15 crores, reflecting ongoing capital expenditure to expand diagnostic capacity.
Cash Flow Dynamics: Working Capital Pressures Persist
Krsnaa Diagnostics' cash flow statement for FY26 reveals persistent working capital challenges. Despite reporting profit before tax of ₹102.00 crores, the company generated operating cash flow of only ₹87.00 crores after adjustments of ₹98.00 crores and adverse working capital changes of ₹93.00 crores. The negative working capital movement—primarily driven by increased receivables and inventory—has been a recurring issue, with similar outflows of ₹96.00 crores in FY25.
Investing cash flow remained negative at ₹99.00 crores in FY26, marginally lower than ₹128.00 crores in FY25, reflecting continued capital expenditure on diagnostic equipment and infrastructure. Financing cash flow turned positive at ₹13.00 crores compared to ₹84.00 crores in FY25, as the company moderated fresh borrowings. The net cash position remained constrained at ₹3.00 crores, up from ₹2.00 crores in FY25, highlighting limited financial flexibility.
Working Capital: A Persistent Drag
The company's working capital absorption of ₹93.00 crores in FY26 (following ₹96.00 crores in FY25) reflects the inherent challenges in the public-sector diagnostic services business, where payment cycles can be extended. With current assets of ₹414.47 crores against current liabilities of ₹305.39 crores, the current ratio stands at a healthy 1.36x. However, the quality of receivables and the efficiency of collections remain critical monitoring points.
Peer Comparison: Valuation Discount Reflects Quality Gap
Krsnaa Diagnostics trades at a significant valuation discount to its healthcare services peers, reflecting concerns about profitability and capital efficiency. At a price-to-earnings ratio of 22.26x, the company is valued at less than half the sector average P/E of approximately 54x and substantially below peers such as Metropolis Healthcare (55.35x), Thyrocare Technologies (46.64x), and Nephrocare Health Services (79.53x).
| Company | P/E (TTM) | P/BV | ROE (%) | Debt/Equity | Div Yield (%) |
|---|---|---|---|---|---|
| Krsnaa Diagnostics | 22.26 | 1.94 | 8.50 | 0.17 | 0.50 |
| Metropolis Healthcare | 55.35 | 7.19 | 14.57 | 0.02 | 0.38 |
| Thyrocare Technologies | 46.64 | 13.38 | 20.88 | -0.29 | 1.90 |
| Nephrocare Health | 79.53 | 5.56 | — | 0.00 | — |
| Vimta Labs | 33.65 | 6.00 | 15.44 | -0.05 | 0.22 |
The valuation discount is justified by Krsnaa Diagnostics' inferior return metrics. With an ROE of 8.50%, the company lags substantially behind Thyrocare Technologies (20.88%), Vimta Labs (15.44%), and Metropolis Healthcare (14.57%). The price-to-book ratio of 1.94x—the lowest among listed peers—reflects market scepticism about the company's ability to generate superior returns on invested capital.
Krsnaa Diagnostics' market capitalisation of ₹1,823 crores positions it as the sixth-largest player in the peer group, limiting its ability to compete for large contracts or achieve economies of scale enjoyed by larger rivals. The company's dividend yield of 0.50% is modest, with a conservative payout ratio of 11.44% indicating management's preference to retain earnings for growth investments.
Valuation Analysis: Attractive Entry Point or Value Trap?
At the current market price of ₹561.90, Krsnaa Diagnostics appears attractively valued on conventional metrics, but the quality concerns warrant caution. The stock trades at a P/E ratio of 22.26x based on trailing twelve-month earnings—a 59% discount to the sector average. The EV/EBITDA multiple of 9.27x and EV/Sales ratio of 2.54x also suggest reasonable valuation, particularly given the company's 18.36% five-year sales growth and 21.98% EBIT growth.
However, the stock's 36.99% decline from its 52-week high of ₹891.80 reflects persistent concerns about earnings quality and growth sustainability. The PEG ratio of 3.86x suggests the stock is not particularly cheap relative to growth prospects. Krsnaa Diagnostics' valuation grade has oscillated between "Attractive" and "Very Attractive" over the past year, currently standing at "Attractive"—a reflection of the market's ambivalence.
The price-to-book ratio of 1.94x implies the market values the company's assets at less than twice their book value, compared to 7.19x for Metropolis Healthcare and 13.38x for Thyrocare Technologies. This valuation gap persists because Krsnaa Diagnostics generates an ROE of only 8.50%—well below the cost of equity for a small-cap healthcare stock—whereas peers deliver ROEs in the 14-21% range, justifying their premium valuations.
Shareholding Pattern: Stable Base with Modest Institutional Interest
Krsnaa Diagnostics' shareholding pattern reveals a stable promoter base and modest institutional participation. Promoter holding remained unchanged at 27.11% in Q4 FY26, having declined marginally from 27.24% in Q4 FY25. The absence of promoter pledging is a positive, indicating confidence and financial stability at the promoter level.
| Shareholder Category | Mar'26 | Dec'25 | Sep'25 | QoQ Change |
|---|---|---|---|---|
| Promoter | 27.11% | 27.11% | 27.11% | 0.00% |
| FII | 3.91% | 4.17% | 3.67% | -0.26% |
| Mutual Funds | 10.17% | 10.15% | 10.46% | +0.02% |
| Insurance | 2.67% | 2.67% | 2.67% | 0.00% |
| Other DII | 1.05% | 1.03% | 1.83% | +0.02% |
| Non-Institutional | 55.08% | 54.85% | 54.26% | +0.23% |
Institutional holdings totalled 17.80% as of Q4 FY26, with mutual funds representing the largest institutional category at 10.17%, followed by foreign institutional investors at 3.91%, insurance companies at 2.67%, and other domestic institutional investors at 1.05%. The sequential decline in FII holding by 0.26 percentage points during Q4 FY26 suggests foreign investors trimmed positions despite the strong quarterly results, possibly reflecting scepticism about earnings sustainability.
Mutual fund holdings edged up marginally by 0.02 percentage points to 10.17% in Q4 FY26, indicating stable domestic institutional interest. The non-institutional shareholding—comprising retail and high-net-worth investors—increased to 55.08% from 54.85%, suggesting some retail accumulation. However, the relatively low institutional holding of 17.80% reflects limited conviction among sophisticated investors, who typically demand consistent earnings quality and superior return metrics.
Stock Performance: Persistent Underperformance Across Timeframes
Krsnaa Diagnostics has significantly underperformed both the broader market and its healthcare services sector across most timeframes, raising concerns about the investment thesis. Over the past year, the stock declined 12.89% compared to the Sensex's 7.25% decline, generating negative alpha of 5.64 percentage points. More alarmingly, the stock underperformed its healthcare services sector by 31.77 percentage points, with the sector delivering positive returns of 18.88% over the same period.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | -0.70% | +1.35% | -2.05% |
| 1 Month | -6.70% | -0.58% | -6.12% |
| 3 Months | -12.07% | -7.33% | -4.74% |
| 6 Months | -30.84% | -10.97% | -19.87% |
| YTD | -22.00% | -10.56% | -11.44% |
| 1 Year | -12.89% | -7.25% | -5.64% |
| 2 Years | -4.74% | +1.07% | -5.81% |
| 3 Years | +11.63% | +21.95% | -10.32% |
The stock's six-month decline of 30.84% is particularly concerning, representing a 19.87 percentage point underperformance versus the Sensex. Year-to-date, the stock has fallen 22.00% compared to the Sensex's 10.56% decline, generating negative alpha of 11.44 percentage points. Even over a three-year horizon, where the stock posted positive returns of 11.63%, it underperformed the Sensex's 21.95% gain by 10.32 percentage points.
Technical indicators paint a uniformly bearish picture. The stock currently trades below all key moving averages—5-day (₹562.09), 20-day (₹582.36), 50-day (₹587.70), 100-day (₹639.15), and 200-day (₹719.76)—indicating sustained selling pressure. The technical trend turned bearish on May 12, 2026, at ₹585.70, following a period of mildly bearish sentiment. MACD shows conflicting signals (mildly bullish weekly, mildly bearish monthly), while Bollinger Bands indicate bearish conditions on both weekly and monthly timeframes.
The stock's beta of 1.35 indicates higher volatility than the broader market, with annualised volatility of 31.47% compared to the Sensex's 13.00%. The risk-adjusted return of -0.41 over the past year, compared to the Sensex's -0.56, suggests the stock has delivered poor returns relative to the risk assumed. The classification as "Medium Risk Low Return" accurately captures the investment profile—elevated volatility without commensurate returns.
Investment Thesis: Growth Potential Offset by Quality Concerns
Krsnaa Diagnostics presents a nuanced investment proposition characterised by solid long-term growth potential offset by persistent concerns about profitability, return metrics, and earnings quality. The company's five-year sales CAGR of 18.36% and EBIT CAGR of 21.98% demonstrate the underlying business opportunity in India's expanding diagnostic services market, particularly in the underserved public healthcare segment where Krsnaa operates.
The company's balance sheet strength—with low leverage (debt-to-equity of 0.17), manageable debt-to-EBITDA of 0.83, and zero promoter pledging—provides financial stability. The adequate EBIT-to-interest coverage of 5.67x offers a buffer against rising interest rates. However, these positives are overshadowed by weak capital efficiency metrics, with ROE of 8.50% and ROCE of 11.77% falling well short of the cost of capital for a small-cap growth stock.
The quality grade of "Good" reflects the company's solid long-term financial performance and balance sheet health, but the recent downgrade from "Good" to "Average" in February 2026 signals deteriorating fundamentals. The persistent negative free cash flow, driven by working capital absorption and capital expenditure requirements, constrains the company's financial flexibility and dividend-paying capacity.
Key Strengths & Risk Factors
✓ Key Strengths
- Strong Revenue Growth: Five-year sales CAGR of 18.36% demonstrates robust business expansion in diagnostic services
- Low Leverage: Debt-to-equity of 0.17 and debt-to-EBITDA of 0.83 indicate conservative capital structure
- No Promoter Pledging: Zero pledged shares reflect promoter confidence and financial stability
- Public-Private Partnership Model: Government contracts provide revenue visibility and lower customer acquisition costs
- Attractive Valuation: P/E of 22.26x represents 59% discount to sector average, offering value opportunity
- Expanding Infrastructure: Fixed assets grew to ₹670.38 crores, supporting capacity expansion
- Improving Operating Margins: Operating margin (excluding other income) improved to 28.49% in Q4 FY26
⚠ Key Concerns
- Weak Return Metrics: ROE of 8.50% and ROCE of 11.77% significantly lag peers and cost of capital
- Earnings Quality Issues: Q4 FY26 profit surge driven by exceptional other income of ₹31.50 crores, not operational performance
- Working Capital Pressures: Persistent negative working capital changes (₹93 crores in FY26) constrain cash generation
- Persistent Underperformance: Stock declined 12.89% over past year, underperforming sector by 31.77 percentage points
- Low Institutional Holding: Only 17.80% institutional ownership reflects limited conviction among sophisticated investors
- Technical Weakness: Trading below all key moving averages with bearish trend since May 12, 2026
- Modest Dividend: Yield of 0.50% with 11.44% payout ratio offers limited income appeal
Outlook: What to Watch
Positive Catalysts
- Sustained improvement in operating margins (excluding other income) above 28% for multiple quarters
- Improvement in ROE towards 12-15% range through better asset utilisation and profitability
- Normalisation of working capital cycle with positive operating cash flow generation
- New government contract wins expanding revenue base and geographic reach
- Reduction in volatility of "other income" to below ₹5 crores per quarter
Red Flags
- Continued reliance on exceptional other income to meet profit expectations
- Further deterioration in working capital with operating cash flow turning negative
- Decline in operating margins (excluding other income) below 26% indicating pricing pressure
- Increase in debt levels beyond current conservative position
- Continued institutional selling with FII/MF holdings declining below 12%
The Verdict: Cautious Accumulation for Patient Investors
Score: 58/100
For Fresh Investors: Consider small position accumulation only on further corrections towards ₹500-520 levels. The attractive valuation (P/E of 22.26x) and solid long-term growth (18.36% sales CAGR) offer value, but weak return metrics (8.50% ROE) and earnings quality concerns warrant caution. Limit exposure to 2-3% of portfolio with a 2-3 year investment horizon.
For Existing Holders: Maintain positions but avoid averaging up until sustainable operational improvements materialise. The Q4 FY26 profit surge was driven by exceptional other income rather than core business strength. Monitor quarterly results for normalised profitability trends and working capital improvements. Consider partial profit booking if stock rallies above ₹650 without fundamental improvement.
Fair Value Estimate: ₹620-650 (10-16% upside from current levels), contingent upon sustainable improvement in ROE above 10% and normalisation of other income
Note- ROCE= (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions.
